Melanoma Biotech Secures Nasdaq Listing via All-Share Merger

Neuphoria Therapeutics Inc. (NEUP:NASDAQ), a U.S. clinical-stage biotechnology company focused on neuropsychiatric disorders, has reached a definitive all-share merger agreement that positions its shareholders for dual value creation. Under the deal announced July 23, 2026, Neuphoria will become a wholly owned subsidiary of Scancell Holdings Plc while its stockholders receive Scancell American Depositary Shares (ADSs) plus contingent value rights. The transaction delivers immediate exposure to a late-stage oncology asset and preserves upside from Neuphoria’s existing partnered programs.

Key Investor Takeaways

• Neuphoria stockholders will receive approximately 20.4 million Scancell ADSs (at an exchange ratio of 37.77199), representing roughly 13.7 percent of the enlarged ordinary share capital, plus non-transferable contingent value rights (CVRs).
• The CVRs entitle holders to future cash payments, if any, from milestones on Neuphoria’s partnered assets (including collaborations with Merck Sharp & Dohme and a Pfizer license related to KAT6) and from an Australian R&D tax credit for the year ended June 30, 2026.
• Scancell is concurrently raising up to $89 million in equity and debt financing that, together with Neuphoria’s cash, is expected to leave the combined group with approximately $79.1 million in pro forma net cash to fund a registrational Phase 3 trial of iSCIB1+ in advanced melanoma.
• iSCIB1+ holds FDA Fast Track designation and previously demonstrated 77 percent progression-free survival at 22 months when combined with ipilimumab and nivolumab.
• Neuphoria halted development of its lead candidate, BNC210, after the Phase 3 AFFIRM-1 trial in social anxiety disorder missed primary and secondary endpoints in October 2025; the company has since conducted a strategic review.
• Closing is targeted for late Q4 2026, subject to shareholder approvals, SEC review of the Nasdaq listing, and receipt of at least $75 million of the financing package.

Why the Merger Matters for Neuphoria Investors Right Now

After the October 2025 Phase 3 failure of BNC210, Neuphoria initiated a strategic review and explored multiple paths to maximize shareholder value. The all-share merger with Scancell provides a clean resolution: Neuphoria shareholders exchange their shares for a meaningful minority stake in a company that is simultaneously securing the capital needed to advance a late-stage cancer immunotherapy into a registrational trial. At the same time, the CVR structure ensures that any future value from Neuphoria’s partnered assets and intellectual property is not left behind.

On July 23, 2026, the two companies announced a merger agreement under which each outstanding share of Neuphoria common stock will convert into Scancell ADSs at the fixed exchange ratio of 37.77199, plus one CVR. Based on current assumptions, Neuphoria stockholders are expected to receive approximately 20,414,065 ADSs, representing about 13.7 percent of Scancell’s enlarged issued ordinary share capital at completion. When non-voting shares issued in the concurrent financing are included, Neuphoria holders are projected to own approximately 11.1 percent of the total outstanding share capital.

Neuphoria’s Strategic Review Outcome and Cash Position

Neuphoria is a clinical-stage biotech dedicated to therapies for neuropsychiatric disorders. Its lead program, BNC210, an oral negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor, failed to meet endpoints in the AFFIRM-1 Phase 3 trial for social anxiety disorder. Development in that indication was stopped, and the board launched a strategic review.

As of March 31, 2026, Neuphoria held US$19.4 million in cash, reported no ongoing revenue, and posted a net loss of US$0.5 million for the quarter. Under the merger terms, Scancell does not intend to advance Neuphoria’s non-partnered pipeline assets. Instead, the CVRs capture potential value from existing licensing agreements, including the collaboration with Merck Sharp & Dohme and the Pfizer license related to KAT6, as well as the pending Australian R&D tax credit.

Transaction Structure and Financing Details

The merger is an all-share transaction. Scancell will issue 20,414,065 ADSs (representing 204,140,654 ordinary shares) to Neuphoria stockholders. Concurrently, Scancell has lined up a multi-tranche financing package intended to fund the global Phase 3 registrational study of its lead asset, iSCIB1+.

• Private Placement: US$39.1 million through the issue of 324,190,865 new ordinary shares (including shares to be represented by ADSs) and non-voting ordinary shares at a placement price of US$0.1205 per ADS or share.
• U.K. Placing and Retail Offer: approximately US$12.0 million via a U.K. placing plus up to a further US$3.0 million retail offer at 9 pence per ordinary share (the GBP equivalent of the placement price). These U.K. components are not conditional on the U.S. listing transactions.
• Debt Financing: non-binding term sheet with certain funds and accounts managed by BlackRock, Inc. (BLK:NYSE) for up to US$25 million of new debt.

Subject to completion of the U.S. listing transactions expected in late Q4 2026, the combined group is projected to have a pro forma net cash balance of approximately US$79.1 million before transaction costs. Closing of the merger itself requires that at least US$75 million of the financing package has been secured. A planned 10-for-1 share consolidation at Scancell is intended to align the ADS price with typical U.S. market expectations.

Scancell’s Lead Asset and the Phase 3 Opportunity

While the narrative centers on Neuphoria’s outcome, the primary near-term catalyst for the combined company is Scancell’s iSCIB1+, an active immunotherapy designed to stimulate durable anti-tumor responses. The candidate holds an FDA Fast Track designation for advanced melanoma. In the Phase 2 SCOPE study, iSCIB1+ combined with the checkpoint inhibitors ipilimumab and nivolumab produced 77 percent progression-free survival at 22 months. Additional survival data from that study are expected within the next 12 months. The newly raised capital is earmarked to support a global registrational Phase 3 trial.

Scancell is a U.K.-based late-stage clinical biotech focused on DNA ImmunoBody and other platforms aimed at generating long-lasting anti-cancer immune responses. The Nasdaq listing under the proposed ticker SCLT is intended to broaden access to U.S. specialist life sciences investors.

Industry Backdrop: Oncology Demand and Capital Environment

The broader market context supports continued investment in innovative cancer therapies. In February 2026, Iqvia discussed the global pharma market projection for 2026, noting that total drug usage is expected to surpass four trillion doses daily by 2030. The largest drivers of spending growth are projected to remain innovative therapeutics, especially in oncology, immunology, diabetes, and obesity.

Pharma sector funding declined between 2024 and 2025, according to a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor. He observed that 2025 was still the third-best year of the past decade and remained well above pre-pandemic norms.

Cancer incidence continues to rise. A March 26, 2026, article by Kinjel Shah for Yahoo Finance claimed that cancer incidences were rising, citing American Cancer Society estimates of 2.1 million new cases and more than 626,000 cancer-related deaths expected in the United States in 2026. Emerging tools such as genomic sequencing, artificial intelligence, and machine learning are accelerating biomarker discovery and earlier diagnosis, yet treatment costs remain high. Keith Speights wrote an article for The Motley Fool discussing rising care costs, noting that U.S. cancer treatment spending was roughly US$200 billion in 2020 and is projected to exceed US$245 billion by 2030.

BCG talked about trends biopharma companies need to be aware of in 2026, emphasizing the need to reduce the complexity and cost of advanced therapies while aligning trial designs with real-world use and market-access requirements.

Analyst Perspective on the Neuphoria Outcome

Following the announcement, Joseph Pantginis, Ph.D., of H.C. Wainwright & Co. described the merger as a constructive outcome of Neuphoria’s strategic review. Maintaining a Neutral rating without a price target, he noted that the approximate 14.5 percent ownership stake in the combined company gives Neuphoria shareholders exposure to Scancell’s oncology pipeline while the CVRs preserve potential upside from Neuphoria’s partnered assets.

Ownership and Share Structure

Neuphoria Therapeutics Inc. has a market capitalization of approximately US$20.81 million based on 5.40 million shares outstanding. The 52-week trading range is US$3.19 to US$21.40. ¹Institutional investors hold 34.56 percent of the shares, strategic investors 4.30 percent, management and insiders 3.41 percent, and retail holders the remaining 57.73 percent. Share-structure data are as of July 28, 2026.

Common Questions from Investors

Q: What do Neuphoria shareholders actually receive?
A: Each share of Neuphoria common stock converts into 37.77199 Scancell ADSs plus one contingent value right. The ADSs represent an approximate 13.7 percent stake in the enlarged ordinary share capital; the CVRs provide the right to future cash payments if specified milestones on Neuphoria’s partnered assets or the Australian R&D tax credit are achieved.

Q: What is a contingent value right (CVR)?
A: A CVR is a contractual right to receive additional cash payments if predefined future events occur, such as milestone payments under licensing agreements or receipt of a tax credit. Payments are not guaranteed.

Q: Why is Neuphoria not continuing its own pipeline?
A: After the Phase 3 failure of BNC210, the company conducted a strategic review. The merger terms state that Scancell will not advance Neuphoria’s non-partnered assets; value from partnered programs is instead captured through the CVRs.

Q: When is the deal expected to close, and what are the key conditions?
A: Closing is targeted for late Q4 2026. Conditions include shareholder approval from both companies, SEC review of Scancell’s Nasdaq listing application, and securing at least US$75 million of the planned financing package.

Q: What is the primary use of the new capital?
A: The financing is intended to fund the global registrational Phase 3 trial of Scancell’s lead melanoma immunotherapy, iSCIB1+, which has shown durable efficacy in Phase 2 combination studies and holds FDA Fast Track designation.

The merger offers Neuphoria stockholders a structured exit from a clinical setback while granting participation in a funded late-stage oncology program and retaining economic interest in prior partnerships. Investors should continue to monitor shareholder votes, financing progress, and the planned Nasdaq listing timeline as the transaction moves toward expected completion in late 2026.